A novel atezolizumab-based PD-L1 CAR-NK cell showed potent activity against tumors overexpressing PD-L1 and exhibited a self-amplifying effect by inducing PD-L1 expression on PD-L1 low tumor cells, thereby enhancing cytotoxicity [69]. This evidence concerns the gene CD274 and neoplasm.